Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 9/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135226 | 0.85 | MEN1 (0.38) | MEN1KMT2ACNR2CNR1TSHR | |
| SCHEMBL5135205 | 0.82 | CXCR3 (0.40) | MEN1KMT2AC5AR1 | |
| SCHEMBL5136271 | 0.82 | MEN1 (0.37) | MEN1KMT2ACNR2LTB4R2PDK1 | |
| SCHEMBL14586255 | 0.78 | TSHR (0.46) | KMT2ATSHRC5AR1 | |
| SCHEMBL14415668 | 0.76 | MEN1 (0.38) | MEN1KMT2ACNR2TSHRLTB4R2 | |
| SCHEMBL14415577 | 0.75 | C5AR1 (0.52) | TSHRC5AR1 | |
| SCHEMBL1912763 | 0.75 | C5AR1 (0.58) | TSHRC5AR1 | |
| SCHEMBL5136275 | 0.75 | MEN1 (0.38) | MEN1KMT2ATSHR | |
| SCHEMBL649271 | 0.74 | AGTR1 (0.42) | MEN1KMT2ATSHR | |
| SCHEMBL5134650 | 0.73 | CNR2 (0.53) | MEN1KMT2ACNR2CNR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |